James A. Sethian is a Professor in the Department of Mathematics at the University of California, Berkeley , with additional affiliation at Lawrence Berkeley National Laboratory . His work focuses on developing and applying Level Set Methods and Fast Marching Methods to track evolving interfaces across diverse scientific domains. Education: Ph.D. in Applied Mathematics , University of California, Berkeley (1982) B.A. in Mathematics, Princeton University (1976) Research spans Applied Mathematics , Computational Physics , and Numerical Analysis , with applications in Semiconductor Manufacturing , Fluid Dynamics , Medical Imaging , Image Processing , Seismic Analysis , and Optimal Control . His publications demonstrate expertise in modeling interfaces that develop sharp corners, break apart, and merge, particularly through PDE-based numerical techniques. Key contributions include algorithms for noise removal , minimal surface computation , and multi-layer coating flows . As a mentor, he has advised numerous PhD students in computational methods and applied mathematics, including Robert I. Saye , Jon Arthur Wilkening , and David Layne Chopp . Projects under his leadership integrate ViscoElastic Flow , Tumor Modeling , and Robotics via curvature-driven evolution and interface tracking.
Joe Pitt-Francis is Associate Professor of Computer Science and Tutorial Fellow in Computer Science at St Edmund Hall, University of Oxford . Since 1999 he has tutored Oxford computer-science students and formally became a Tutorial Fellow of St Edmund Hall in 2024. His research lies at the intersection of computational biology and mathematical biology . Using sophisticated numerical techniques he constructs and analyses models of the heart , cancer and blood flow . A central strand of his work is software development for biological simulation; he is an active contributor to Chaste ( Cancer, Heart and Soft-Tissue Environment ), a large-scale C++ library that supports multiscale computational models in physiology and medicine. Across more than 60 peer-reviewed publications since 1998, his work has progressively advanced from foundational software-engineering papers describing Chaste’s architecture to highly-cited studies on cardiac electrophysiology , tumour-induced angiogenesis , microvascular haemodynamics and cell-cycle dynamics under hypoxia . The 2024-2025 corpus shows strong emphasis on multiscale frameworks , open benchmarking , and radiotherapy-induced vascular remodelling , positioning his group at the forefront of translational in-silico oncology. Contact: Email: Joe.Pitt-Francis@seh.ox.ac.uk
Philipp Neumann is a Professor and Chair of High-Performance Computing at Helmut Schmidt University since 2019. Previously, he held roles including Senior Researcher at the German Climate Computing Center (2016–2019), Postdoc at the University of Hamburg (2017–2019), and completed his Habilitation in Scientific Computing at TU Munich (2019). He transitioned to DESY/Universität Hamburg in May 2024. Education : PhD (Dr. rer. nat.) in Scientific Computing at TU Munich (2008–2013) Habilitation in Scientific Computing at TU Munich (2019) Studies in Technomathematics at Friedrich-Alexander University Erlangen-Nuremberg (2003–2008) Research Interests focus on high-performance computing, parallel and distributed systems, computational science, and applications in climate modeling. His work bridges computational methods with medical challenges, including surgical simulation training, wound healing mechanisms, and gastrointestinal pathology. Professional Activities include leadership roles in major conferences such as steering committee member for ISPDC (since 2021) and program committee roles in IPDPS, ICCS, and IEEE Cluster. He also managed the DFG priority program SPPEXA (2013–2016). Labs/Teams include the Chair for High-Performance Computing at Helmut Schmidt University and collaborations with the German Climate Computing Center. His current work at DESY/Universität Hamburg likely expands these computational efforts into interdisciplinary research.
Dr. Su Ryon Shin is an Assistant Professor in the Division of Engineering in Medicine at Harvard Medical School and Brigham and Women's Hospital (BWH) in Cambridge, MA. She leads an active research laboratory focused on bioengineering, tissue engineering, and regenerative medicine, with particular expertise in 3D bioprinting, biomaterials, and organ-on-a-chip technology. Her research interests span biohybrid robotics, decellularized extracellular matrix, stem cell-based tissue engineering, and volumetric muscle regeneration . Dr. Shin's work integrates advanced biomaterials with cellular systems to create innovative solutions for tissue regeneration and disease modeling. She has pioneered approaches using human stem cell-derived materials for volumetric tissue regeneration and developed biohybrid neuromuscular robots powered by living cardiac muscle cells. Her publication record demonstrates consistent productivity with over 180 publications, including numerous first/senior author papers in high-impact journals like Science Robotics, Advanced Materials, and Nature Reviews Bioengineering . Her work shows a clear progression from fundamental biomaterials development to increasingly complex tissue engineering applications and translational research. Dr. Shin has received significant recognition including being named a 2025 BWH Health & Technology Innovation Awardee , Highly Cited Researcher 2024 by Web of Science, and multiple Stepping Strong Innovator Awards (2015, 2018, 2020). Her research has been featured in Nature Reviews Bioengineering for breakthrough work on biohybrid robots. She actively mentors students and postdocs, with former lab members accepted to prestigious programs like MIT's PhD program in Chemical Engineering. Her collaborative approach is evident through numerous interdisciplinary projects with researchers across Harvard Medical School, BWH, and international institutions.
Prof. Robbert Jan Kok is a Professor of Drug Delivery Technology at Utrecht University's Utrecht Institute for Pharmaceutical Sciences (UIPS) and Programme Director for the Bachelor of Pharmacy. He obtained his Pharmacy degree (1993) and PhD in renal drug targeting (1998) from the University of Groningen, followed by postdoctoral research on endothelial-targeted drug delivery. His work spans curriculum development for pharmacy programs and interdisciplinary research in drug innovation. Research Focus: Kok specializes in advanced drug delivery systems, including nanomedicines for kinase inhibitors, 3D-printed formulations, and stimuli-responsive carriers. Key areas include: Targeted delivery to tumors, kidneys, and inflamed tissues Polymeric micelles, liposomes, and microspheres for sustained release Biopharmaceutics and pharmacokinetic optimization Publication Trends: His recent work emphasizes nanotechnology-enabled therapies (e.g., curcumin nanodelivery, photodynamic micelles) and device-integrated drug release (3D-printed implants, macroencapsulation). Studies frequently combine material science with preclinical validation in cancer, renal diseases, and inflammatory disorders. Academic Leadership: Kok oversees student advising, laboratory operations, and international collaborations at UIPS. His team explores translational applications of drug delivery platforms, including partnerships for vascularized tissue engineering and combination therapies.
Michael Harrison is an Assistant Professor in the Department of Cell and Developmental Biology at Weill Cornell Medicine, where he leads the Regeneration and Development Lab within the Graduate School of Medical Sciences. His research focuses on vascular development and regeneration using zebrafish as a model organism, with emphasis on coronary and cerebral vasculature. Education: B.Sc. in Genetics, University of Edinburgh (2005) Ph.D. in Developmental Genetics, University of Sheffield (mentor: Vincent Cunliffe) Postdoctoral Fellowship, Saban Research Institute, Children’s Hospital Los Angeles (CIRM Fellow) Harrison's research centers on understanding how blood and lymphatic vessels form and regenerate, particularly in the heart and brain. His lab investigates coronary vessel development, the role of lymphatic systems in inflammation and regeneration, and revascularization after injury. By leveraging zebrafish genetics and advanced imaging, his work aims to uncover pathways that could be harnessed for regenerative therapies in humans. His recent publications reveal key signaling mechanisms such as Cxcr4-Cxcl12 in coronary development and the two-step formation of cardiac lymphatics. The 15 most recent articles demonstrate a strong, consistent research trajectory in vascular biology and regeneration, with increasing use of advanced techniques like single-nuclei multiomics, fluidic imaging devices, and CRISPR-based genome editing. His work spans developmental mechanisms, functional imaging, and translational applications in cardiac repair. Scientific Awards: No awards explicitly mentioned in the provided text. Harrison actively mentors a team of postdoctoral fellows, research assistants, and students, several of whom have progressed to medical school or research careers. His lab collaborates extensively, particularly with Ching-Ling Lien's group. He has secured research space and funding to support ongoing projects in cardiac and cerebral vasculature. The lab is actively recruiting rotation students from BCMB, PBSB, IMP, and Tri-Institutional programs, as well as postdoctoral researchers and research assistants, indicating an expanding research team and active grant support. Labs and Teams: Regeneration and Development Lab, Weill Cornell Medicine Collaborations with Ching-Ling Lien Lab Member of Tri-Institutional PhD Programs Active participation in BCMB, PBSB, and IMP training programs
João F. Mano is a Full Professor at the Department of Chemistry, University of Aveiro, and Director of the Doctoral Program on Biotechnology. He leads the COMPASS Research Group and serves as Vice-Director at CICECO - Aveiro Institute of Materials. His academic appointments include Invited Professor at University of Lorraine (France), Visiting Professor at KAIST (South Korea), and Adjunct Professor at Ajou University (South Korea). Education: PhD in Chemistry (1996, Technical University of Lisbon); D.Sc. in Tissue Engineering, Regenerative Medicine and Stem Cells (2012, University of Minho) Research Interests focus on Biomaterials for Regenerative Medicine , integrating Nanotechnology , Microtechnology , and Biofabrication . His group develops Bioinspired Materials using polymer chemistry, Decellularized Extracellular Matrix , and 3D Bioprinting to engineer Cell Microenvironments for therapeutic applications. Recent Publications highlight advancements in Human-Derived Hydrogels , Photopolymerizable Scaffolds , Magneto-Responsive Biomaterials , and Programmable Bioinks . Trends show emphasis on Organ-on-a-Chip integration, Smart Living Materials , and Green Bioprinting methodologies. Scientific Awards include: European Research Council Advanced Grants (2015, 2020) Fellow at IUPAC, European Academy of Sciences, and American Institute of Medical and Biological Engineering ERC Proof of Concept Grants Doctor Honoris Causa from University of Lorraine and Utrecht UNESCO Chair on Biomaterials George Winter Award (European Society for Biomaterials) Supervisions & Collaborations encompass 74+ MSc, 26+ PhD students, and 40+ postdocs. He co-founded METATISSUE and CELLULARIS Biomodels , and serves as Editor-in-Chief of Materials Today Bio .
Yeonhwa Park is a Professor and holder of the Francis Chair in the Department of Food Science at the University of Massachusetts Amherst. Her research focuses on functional foods, bioactive components, and environmental contaminants' effects on obesity and aging. She investigates food bioactives like conjugated linoleic acid (CLA) and environmental pollutants like PFAS to understand their roles in metabolic disorders and aging mechanisms. Her work spans multiple models, including C. elegans, zebrafish, and rodent studies, emphasizing translational applications for human health. Teaching responsibilities include courses such as 'Science of Food' (FS150), 'Biology of Food in Human Health' (FS270), and 'Bioactive Food Components' (FS750). Awards include Clarivate Highly Cited Researcher (2017–2018), Faculty Convocation Award (2015), and the Timothy Mounts Award (2015). Her research has been published in over 150 peer-reviewed articles, with recent emphasis on environmental contaminants' impact on obesity and type 2 diabetes, and the use of C. elegans for screening bioactives. Key findings include CLA's role in fat reduction, PFAS-induced metabolic disruption, and the application of alternative models (e.g., C. elegans) to reduce animal testing. Her lab integrates molecular biology, toxicology, and food science to address global health challenges like the obesity epidemic and environmental toxin exposure.
Shutao Ma is a Professor and Doctoral Supervisor at Shandong University's School of Pharmaceutical Sciences, serving as Director of the Department of Medicinal Chemistry since 2009. He has received the Special Government Allowance from China's State Council since 2002 and the seventh youth award of Shandong province for his contributions to medicinal chemistry. His academic credentials include: Ph.D. in Pharmaceutical Sciences, Shandong University (2004-2007) M.Sc. in Pharmaceutical Sciences, Shandong Medical University (1988-1991) B.Sc. in Pharmaceutical Sciences, Shandong Medical University (1981-1986) Professor Ma's research pioneers innovative strategies against antibiotic-resistant bacteria through three interconnected pillars: 1) Designing FtsZ/AcrB-targeted small molecules to disrupt bacterial cell division and efflux mechanisms; 2) Structural optimization of macrolides, glycopeptides, and lipopeptides to overcome resistance; 3) Total synthesis and mechanistic studies of marine-derived antibacterial natural products. His work bridges synthetic chemistry with microbiological validation to develop next-generation antimicrobials. Analysis of his 15 most recent publications (2014-2016) reveals a dominant focus on antibacterial drug discovery (87% of works), particularly FtsZ inhibitors (33%) and macrolide derivatives (27%). Emerging themes include quorum sensing modulation (7%) and antiviral/anticancer applications (13%), demonstrating strategic expansion while maintaining core expertise in resistance mechanisms. His scientific recognition includes: First prize of Shandong science and technology progress award (2000) Special government allowance from the State Council (2002) The seventh youth awards of Shandong province (2002) As a Doctoral Supervisor, Professor Ma mentors the next generation of medicinal chemists while directing a robust research program funded by 12 major grants. His National Natural Science Foundation portfolio (2004-2020) spans antibacterial discovery, while Shandong Provincial grants (2006-2017) and China-Australia collaborations (2014-2017) support translational development of resistance-breaking agents. Leading the Department of Medicinal Chemistry, he oversees a multidisciplinary team integrating synthetic chemistry, microbiology, and computational modeling to advance antibacterial drug candidates from concept to preclinical validation, with particular emphasis on FtsZ-targeted therapeutics and macrolide engineering.
James McGrath is a Professor of Biomedical Engineering at the University of Rochester, holding the William R. Kenan, Jr. Professorship. He leads the Nanomembrane Research Group, pioneering ultrathin silicon nanomembrane technologies for biomedical applications. His work integrates material science, microfluidics, and tissue engineering to address challenges in diagnostics, regenerative medicine, and environmental health. McGrath's interdisciplinary team collaborates across academia and industry, including the Rochester-based SiMPore Inc. (co-founded by him). Education: B.S. Mechanical Engineering, Arizona State University (1991) M.S. Mechanical Engineering, MIT (1994) Ph.D. Biological Engineering, Harvard/MIT (1998) Research Interests: McGrath focuses on nanomembrane technologies for: Microphysiological systems (organ-on-a-chip) Biosensors and diagnostic tools Hemodialysis and toxin removal Microplastics detection in water and biological systems Inflammatory fibrosis modeling (e.g., blood-brain barrier dynamics) Extracellular vesicle biomarker platforms Awards & Recognition: Edmund A. Hajim Outstanding Faculty Award (2019) AIMBE Fellow (2015) William R. Kenan, Jr. Professorship (2023) Advising & Industry: McGrath has advised students and entrepreneurs through his lab and SiMPore Inc., focusing on translating nanomembrane innovations into clinical and commercial applications. His work bridges basic science and applied engineering, with a focus on scalable manufacturing and global health impact. Labs & Collaborations: The Nanomembrane Research Group collaborates with UR, RIT, and international partners to advance nanomembrane-based solutions for healthcare and environmental challenges. Key platforms include the MicroSiM barrier tissue system and silicon nanomembrane analysis pipelines.
Amjad Javed is a Professor and Associate Dean at the University of Alabama at Birmingham , with primary appointments in the School of Dentistry - Oral & Maxillofacial Surgery and joint affiliations in Cell, Developmental and Integrative Biology , Otolaryngology , and Biomedical Engineering . His research spans bone biology, cartilage development, and myeloma bone disease. PhD in Physiology (University of the Punjab, 2003) MS in Zoology/Animal Biology (University of the Punjab, 1992) Research Interests focus on transcriptional regulation via RUNX2 and Sp7 in skeletogenesis, vascular calcification mechanisms, epigenetic control of bone formation, and tumor-bone microenvironment interactions in multiple myeloma. Key subfields include endochondral ossification, osteoclast differentiation, and nanomatrix-based tissue engineering. Scientific Contributions include discoveries about RUNX2's role in postnatal bone resorption, λ5 protein's impact on skeletal aging, and heparanase's promotion of myeloma metastasis. His work demonstrates RUNX2's dual function in chondrocyte apoptosis and cartilage degradation. Teaching & Mentorship involves graduate committee service for over 15 students and instruction in courses like Connective Tissue and Bone , Oral & Skeletal Biology , and Journal Clubs . Collaborations span Comprehensive Arthritis, Musculoskeletal, Bone and Autoimmunity Center , Integrative Center for Aging Research , and Biomatrix Eng Regen Med Center .
George E. Vates, MD, PhD, is a Professor in the Department of Neurosurgery and the Department of Medicine (Endocrine/Metabolism) at the University of Rochester Medical Center. He serves as neurosurgeon co-director of the University of Rochester Multidisciplinary Neuroendocrinology Clinic and is a key member of the University of Rochester Medical Faculty Group (URMFG), which comprises over 900 providers across 19 departments. Dr. Vates specializes in pituitary tumor surgery, cerebrovascular disorders, and skull base procedures, having performed over 120 transsphenoidal pituitary surgeries. Dr. Vates completed his academic training with exceptional distinction: Duke University: Bachelor's degree, summa cum laude (1988, Phi Beta Kappa) Rockefeller University: PhD in Neuroscience Weill Medical College of Cornell University: MD (1997, Alpha Omega Alpha) University of California, San Francisco: Neurosurgery Residency (1998-2003) Brigham and Women's Hospital, Harvard Medical School: Cerebrovascular/Skull Base Fellowship (2003-2004) His research focuses on pituitary tumor biology, neuroendocrinology, and surgical innovation. He established the Multidisciplinary Neuroendocrinology Clinic as a regional referral center for complex pituitary cases, integrating neurosurgical and endocrinological expertise. Current work emphasizes neuroprotective mechanisms in pituitary adenomas, surgical simulation technology, and optimizing outcomes for elderly glioma patients. Analysis of his 15 most recent publications reveals evolving research trajectories: contemporary studies (2019-2022) concentrate on pituitary tumor management, surgical simulation, and neurosurgical education, while earlier work (2002-2009) explored cerebrovascular anomalies, neural pathway mapping, and vascular malformations. Persistent themes include surgical technique refinement, tumor biology, and clinician training. Dr. Vates' scientific contributions have been recognized through: Phi Beta Kappa (1988) and Alpha Omega Alpha (1991) academic honors Neurosurgery Research and Education Foundation Fellowship (2006) Anspach Award for Cerebral Ischemia Research (2007) AANS Leadership Scholarship and Cone Pevehouse Award (2009) Ongoing service as St. Michael's Hospital Animal Care Committee reviewer As an educator, he mentors neurosurgery residents through clinical supervision and curriculum development, notably publishing on palliative care communication training. His research initiatives, including the 3D-printed cervical laminectomy simulator, demonstrate commitment to advancing surgical education. Current grants focus on neuroprotective strategies in pituitary tumors and resident training methodologies. Dr. Vates co-directs the Multidisciplinary Neuroendocrinology Clinic with endocrinologist Dr. Calvi, fostering collaboration between neurosurgery, endocrinology, and oncology. His clinical team manages complex pituitary cases across Rochester and Hornell campuses, while his research group develops surgical innovations and investigates tumor microenvironment interactions to improve patient outcomes.
Prof. Carlijn V.C. Bouten is Full Professor of Cell-Matrix Interactions in Cardiovascular Regeneration at Eindhoven University of Technology (TU/e), where she heads the Soft Tissue Engineering & Mechanobiology research group in the Department of Biomedical Engineering. She leads a team of ~40 researchers focusing on cardiovascular tissue regeneration through interdisciplinary approaches. Her research investigates mechanobiological interactions between cells and extracellular environments during tissue growth/regeneration, using multi-scale living model systems. Key innovations include biodegradable heart valve prostheses, hybrid implantable organs, and remote cardiac tissue engineering concepts. She collaborates with material scientists, clinicians, and medtech companies. Education includes an MSc in Functional Anatomy and Biomechanics (Vrije Universiteit Amsterdam, 1991) and PhD (TU/e, 1995), with postdoctoral training at Université Laval and University of London. Her 300+ publications focus on: Cardiovascular tissue engineering Cell-matrix mechanobiology In vitro tissue models Biodegradable implants Hybrid organ development Major scientific honors: ERC Advanced Grant (2022) VICI Grant (2003) Aspasia Career Development Award Coordinator of €18.8M Gravitation Programme Elected member of KNAW and AcademiaNet She leads multiple consortia including RegMed-XB's Cardiac Moonshot and international programs like FET-OPEN 'Hybrid Heart'. Heads TU/e's Soft Tissue Engineering & Mechanobiology lab developing advanced biomaterials and tissue models.
Dr. Barbara L. Hempstead is a Professor of Neuroscience and Medicine at Weill Cornell Medical College, where she has held positions since 2001 and 2002 respectively. Her research focuses on neurotrophin signaling mechanisms, particularly the roles of BDNF and its receptors in neuroinflammation, synaptic plasticity, and neurodegenerative diseases. She has made significant contributions to understanding proBDNF/proNGF signaling pathways in neuronal apoptosis and vascular biology. Education: M.D., Ph.D., Washington University School of Medicine (1982) B.A., Tufts University (1976) Dr. Hempstead's work bridges molecular neuroscience and cardiovascular biology, with a particular interest in receptor stoichiometry (p75NTR, TrkB), neurotrophin-induced synaptic remodeling, and therapeutic applications of neurotrophin modulators in Huntington's disease and post-seizure neuronal injury. Her lab investigates how genetic variants like BDNF Val66Met influence anxiety-related behaviors, social memory, and neurodegenerative disease progression through altered neurotrophin trafficking and signaling. Her recent publications highlight neuroinflammatory mechanisms (2023), immune-neurotrophin interactions (2022), and molecular pathways involving BDNF prodomain structure (2020) and SorCS2-mediated receptor trafficking (2017-2020). While no scientific awards are explicitly mentioned in the scraped text, her funded research (National Institute on Aging, NIMH) demonstrates sustained recognition of her work in neurotrophin biology. Dr. Hempstead's lab develops in vitro and in vivo models to study neurotrophin-receptor dynamics, including 3D culture systems for angiogenesis research and transgenic mouse models for Huntington's disease. Her interdisciplinary approach combines molecular neurobiology with vascular physiology to uncover novel therapeutic targets for neurological and cardiovascular conditions.
Katherine E. Varley, PhD is a Huntsman Cancer Institute Investigator and Associate Professor in the Department of Oncological Sciences at the University of Utah. She leads the Varley Lab and is a member of the Nuclear Control of Cell Growth and Differentiation Program, focusing on breast cancer genomics, epigenetics, and biomarker discovery. Her work bridges computational biology with clinical applications to improve breast cancer diagnosis and treatment. Dr. Varley earned her BS in Biology with a concentration in Computational Biology from Cornell University in 2003, followed by a PhD in Computational Biology from Washington University School of Medicine in 2009 under Dr. Robi Mitra. Her postdoctoral training was conducted in Dr. Richard M. Myers' laboratory at the HudsonAlpha Institute for Biotechnology, where she participated in the ENCODE Project Consortium. Her research focuses on using next-generation sequencing and computational analysis to study gene expression, transcription factor binding, and DNA methylation patterns in breast cancer. The Varley Lab investigates epigenetic gene regulation, develops novel molecular methods and bioinformatics approaches, and translates discoveries into clinical tools. Key research areas include Clinical Trial Genomics, Epigenome Engineering, Detecting Circulating Tumor DNA, and identifying Transcription Factors Driving Metastasis, with particular emphasis on triple-negative breast cancer. Analysis of Dr. Varley's publications reveals a consistent trajectory from fundamental genomic mechanisms to clinical translation, with recent work emphasizing biomarker discovery, tumor heterogeneity, and the development of genomic tools for precision oncology. Her research spans cancer biology, genomics, and computational analysis to address critical challenges in breast cancer treatment. Dr. Varley holds multiple patents related to cancer diagnostics and genomic technologies, including targeted sequencing methods, multigene assays for recurrence risk, and biomarkers for triple-negative breast cancer. These inventions reflect her commitment to translating basic research into clinical applications. She actively collaborates with clinical investigators in breast cancer trials and works closely with the Breast and Gynecologic Cancers Disease Center at Huntsman Cancer Institute. Her lab maintains four main research thrusts that collectively address breast cancer from molecular mechanisms to clinical applications, demonstrating a comprehensive approach to improving patient outcomes through genomic technologies.
